Rhythm Pharmaceuticals, Inc. (RYTM)
$90.78+1.27%Close
SELLBEAR · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.2B
- Beta
- 1.97
- P/E (TTM)
- -29.19
- Short % float
- 19.34%
- Days to cover
- 14.1
- SI change
- +4.7%
- 1W
- -2.21%
- 1M
- -11.17%
- vs SPY 1W
- -3.37%
- vs SPY 1M
- -14.17%
Industry peers
FMP comparable companies · ranked by market cap
- BMRNSELLBioMarin Pharmaceutical Inc.$10.6BBEARQ 12$54.80-0.16%
- BLTESELLBelite Bio, Inc$6.2BBEARQ 53$154.49+1.29%
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 22$28.51+2.81%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 38$53.24-0.02%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 28$38.37+3.98%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$27.11+4.75%
- GPCRSELLStructure Therapeutics Inc.$1.5BCRISISQ 14$25.54-0.51%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on RYTM?
- LOPJLB’s latest quantitative signal on Rhythm Pharmaceuticals, Inc. (RYTM) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is RYTM in?
- Rhythm Pharmaceuticals, Inc. (RYTM) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Rhythm Pharmaceuticals, Inc. (RYTM) do?
- Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencie…